A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
This study aims to establish a safe and well tolerated dose of \[177Lu\]Lu-DOTA-TATE in combination with carboplatin, etoposide and atezolizumab in this setting and to assess preliminary efficacy of this combination treatment versus the combination of carboplatin, etoposide, and atezolizumab.The study will be essential to assess a new potential therapeutic option in participants with this aggressive cancer type.
Ask AI to explain this studyKey things to know
This describes the study’s primary purpose.
Plus 3 other study approaches.
These are broad labels—not an eligibility decision.
Checked against the public recordLast updated Aug 19, 2026 · Source: ClinicalTrials.gov
The study is underway but is not accepting new participants.
Interventional
Locations may change over time.
Study sponsor
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Novartis Pharmaceuticals
- Interventions being studied
- Drug: [177Lu]Lu-DOTA-TATE; Drug: Atezolizumab; Drug: [68Ga]Ga-DOTA-TATE; Other: Carboplatin; Other: Etoposide
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.
- Key
- Participant is \>= 18 years on the day of signing informed consent form
- Histologically or cytologically confirmed ES-SCLC
- Presence of measurable disease
- No prior systemic treatment for ES-SCLC (except the first cycle of chemotherapy with or without atezolizumab of the induction period
- ECOG status =\< 1
- Provision of tumor tissue to support exploratory biomarker analysis
- Life expectancy of \>= 6 months Key
- Participant has received prior therapy with an antibody or drug against immune checkpoint pathways
- Active autoimmune diseases or history of autoimmune diseases that may relapse
- Severe chronic or active infections (including active tuberculosis, HBV, or HCV infection) requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks before Cycle 1 Day 1
- Any major surgical procedure requiring general anesthesia =\< 28 days before Cycle 1 Day 1
- History or current diagnosis of electrocardiogram (ECG) abnormalities indicating significant risk of safety for participants participating in the study
- Known hypersensitivity to the active substances or any of the excipients of the study drugs
- Concurrent participation in another therapeutic clinical study
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- AdventHealthOrlando, Florida
- University Cancer and Blood Center LLCAthens, Georgia
- University of KentuckyLexington, Kentucky
- St Louis UniversitySt Louis, Missouri
- Hackensack University Medical CtrHackensack, New Jersey
- University Hospitals Of ClevelandCleveland, Ohio
- Fox Chase Cancer CenterPhiladelphia, Pennsylvania
- Novartis Investigative SiteVienna
- Novartis Investigative SiteMontreal, Quebec
- Novartis Investigative SiteBeijing
- Novartis Investigative SiteShanghai
- Novartis Investigative SiteOlomouc
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 19, 2026. Always confirm current availability with the study team.